Today Stories

Abbott published 'Advancing Diversity in Clinical Trials' to share strategies to support diversified clinical trials in healthcare The company continues to build new partnerships designed to improve diverse enrollment in clinical trials, drive education about the research process, and empower diverse patients to improve their care Now in its third year, Abbott's Diversity in Clinical Trials initiative continues to ensure broad, diverse groups of patients are represented in the clinical trials process ABBOTT PARK, Ill. – Nov. 19, 2024 – Abbott today announced that, in the third year of its multi-million-dollar Diversity in Clinical Trials initiative, the company has published 'Advancing Diversity in Clinical Trials' to share strategies to make clinical research and the teams leading these…

An Taoiseach, Simon Harris, TD, and Abbott Chairman and Chief Executive Officer, Robert Ford, attend official opening More than 800 to be employed at the diabetes technology manufacturing site, which is part of a €440 million investment Abbott is making across two sites in Ireland Facility will have the highest production of FreeStyle Libre® sensors in the world Abbott announces $100,000 grant to The Ireland Funds to support the education of young people from three DEIS schools located in Kilkenny ABBOTT PARK, Illinois – Nov. 18, 2024 – Abbott today marked the official opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland with a ceremony attended by An Taoiseach, Simon Harris, TD, and Abbott Chairman and Chief Executive Officer, Robert Ford. The site is a glob…

PORTAGE, Mich., USA – November 14, 2024 – Stryker (NYSE:SYK), a global leader in medical technologies, announced its launch of the next generation of SurgiCount+ within its sponge management portfolio. Now integrated with Stryker’s Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals. Maternal mortality has been rising in the U.S. for decades,1 with approximately 50,000 cases of severe maternal morbidity occurring each year.2 Notably, 70% of pregnancy-related deaths due to hemorrhage are preventable.3 Stryker’s Triton software includes AI technology that can differentiate blood from…

Newly built 45,000 sq ft facility houses engineering and skilled manufacturing employees at Longbridge Business Park, a specialized hub for science and technology. Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth. New facility was constructed to BREEAM Very Good standard and achieved the highest Energy Performance Certificate rating. LONGBRIDGE, United Kingdom – November 13, 2024 – Waters Corporation (NYSE:WAT) announced the official opening of its new 45,000 square foot manufacturing facility at the Longbridge Business Park in the West Midlands. The new facility more than triples existing operations and enhances the company’s machining capacity to produce critical components for products developed and manufacture…

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumors With the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinations BioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 2025 BioNTech to pay $800 million to acquire 100 percent of the issued share capital and up to $150…

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1 DRD is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe.2,3 There is an urgent need for earlier detection of DRD and novel treatments that work in earlier disease states before vision loss occurs.  Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term collaboration as Boehringer becomes the first pharmaceutical company to join the MTM Vision Consortium. Housed at the University of Michigan, the MTM Vision Consortium aims to unite innovators in the pre-competitive space from universities, f…

AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy. AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts A next generation manufacturing facility for biologics in Maryland Cell therapy manufacturing capacity on the West and East Coasts Specialty manufacturing in Texas Pascal Soriot, Chief Executive Officer, AstraZeneca said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the…

Professor Meritxell Huch, a director at the Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany receives this year’s Otto Bayer Award for her pioneering research on human organoids / Four early career scientists are honored with the Early Excellence in Science Awards for their boundary breaking research in the fields of Biology, Chemistry, Data Science and Medical Science. Leverkusen, November 6, 2024 – Professor Meritxell Huch receives this year’s Otto Bayer Award. The Otto Bayer Award is presented alternating with the Hansen Family Award every second year. The award recognizes leading scientists working in German-speaking countries for ground-breaking research in chemistry or biochemistry. The award with a prize money of EUR 75,000 was generou…

STRASBOURG, France and BERLIN, Germany, November 05, 2024 / Biotech Newswire / -- Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a leading CDMO in biologics, vaccines and viral vectors, announce that the companies have entered into a license agreement for ProBioGen’s AGE1.CR.pIX® suspension cell line. This partnership aims to add value by combining ProBioGen’s specific production technology with the manufacturing capabilities of Transgene’s individualized cancer vaccine program and its myvac® platform. ProBioGen’s AGE1.CR.pIX suspension cell line showcases innovation and reliability in bioprocessing with a proven track record and is currently in use for multiple late-stage clinical trials.…

Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard have agreed to collaborate on a project to tackle the urgent and unmet needs of people living with mental health conditions. The collaboration will focus on developing first-in-class treatments that address sleep disturbances associated with cognitive impairment in mental health conditions such as schizophrenia or mood disorders, which have a substantial impact on those affected, but also on their care partners and families. One in eight people are currently living with a serious mental health condition worldwide, and one in two people will experience such a condition in their lifetime. Cognitive impairment is one of the core characteristics of mental health co…

Lund, Sweden – SmiLe company Aligned Bio has successfully completed a financing round, securing SEK 19.4 million to accelerate the development and scale up its nanowire production technology. The company has been accepted into the SmiLe incubator program.  The nanotechnology company Aligned Bio has completed a new share issue to take its unique platform for manufacturing semiconductor nanowires toward commercialization. Both existing shareholders and new investors, including SmiLe Inject Capital, participated in the financing round.  What makes Aligned Bio’s technology unique is its ability to detect individual molecules, significantly improving sensitivity in the analysis of biomolecules. The production of nanowires also becomes simpler and thus more cost-effective than with existing tech…

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immunotherapies, today announced a collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology. The discovery partnership will leverage EvolveImmune's T-cell engager platform to develop novel antibody-based therapies for solid and hematologic malignancies. EvolveImmune's proprietary EVOLVE platfor…

Abbott's world-leading1 FreeStyle Libre 2 and 3 systems for people living with diabetes are now the only continuous glucose monitoring sensors 2 in the U.S. that users do not need to remove during common imaging procedures like X-rays, CT scans and MRIs* ABBOTT PARK, Ill. – Oct. 30, 2024 – Abbott today announced that its FreeStyle Libre 2 and 3 systems can now be worn during common imaging procedures, such as X-rays, CT scans and MRIs*. The U.S. Food and Drug Administration (FDA) cleared the removal of the imaging contraindication, making Abbott’s systems the first and only patient-applied continuous glucose monitoring (CGM) sensors approved for these screenings. People who use FreeStyle Libre 2 and 3 systems rely on their CGM sensors to make important decisions about their diabetes, inc…

The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen. Collaboration leverages Neomorph's leading molecular glue discovery platform and Biogen’s deep expertise in Alzheimer’s, rare, and immunological diseases. CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. As part of the collaboration, the companies aim to utilize Neomorph's proprietary molecular glue discovery platform to accelerate the identification and validation of novel small molecule therapeutic molecular glue degraders. Small m…

Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease Acquisition also allows AbbVie to utilize Aliada's novel blood-brain barrier (BBB)-crossing technology to enhance discovery and development efforts across neuroscience NORTH CHICAGO, Ill. and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. Aliada's lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ…

INDIANAPOLIS, IN / ACCESSWIRE / October 28, 2024 / 3Aware, a pioneer in real-world evidence (RWE) solutions for the medical device industry, is pleased to announce a strategic partnership with RQM+, a leading global MedTech service provider. This collaboration marks a significant step in enhancing regulatory compliance and fostering innovation within the MedTech sector. The partnership will combine 3Aware's advanced aiSurveillance technology with RQM+'s comprehensive regulatory expertise to offer an integrated approach to post-market surveillance and compliance for medical device and IVD manufacturers. This synergy aims to transform how companies meet rigorous regulatory requirements while accelerating label expansion and time to market for new and innovative medical devices. "Joining forc…

The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner in their disease progression ABBOTT PARK, Ill., Oct. 24, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new, first-of-its-kind clinical trial designed to improve outcomes in patients with worsening heart failure who could benefit from advanced therapy options. The TEAM-HF trial, which is planned to enroll up to 850 patients across 75 sites worldwide, will measure pulmonary artery pressures (PAP) using Abbott's CardioMEMS™ HF System to objectively identify advanced heart failure patients at high…

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value Hamburg, Germany, 23 October 2024:Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a programme-based payment of US$ 50 m to Evotec. Based on potential programme-based milestones, the expansion contributes to the deal value. Evo…

Sandwich, Kent, UK / 23 October 2024 / In a bid to enable future success and growth, ten entrepreneurial life science and technology businesses have begun the immersive Discovery Spark programme, with a prize package worth over £50,000 up for grabs. Based in Sandwich, Kent,  Discovery Park is a leading science and innovation campus offering a range of impressive facilities for dynamic start-ups through to global corporations. Now in its third iteration, the Discovery Spark programme equips early stage life science and technology businesses with the skills and tools to lay healthy foundations in their business, refine their commercial strategy and achieve investor readiness. The ten entrepreneurial businesses securing a coveted spot on this cohort and looking to advance their organisation a…

The Cambridge-GSK Translational Immunology Collaboration (CG-TIC) brings together GSK’s expertise in the science of the immune system, AI and clinical development with Cambridge’s complementary expertise GSK is investing more than £50 million in the CG-TIC to further accelerate research and development in kidney and respiratory diseases GSK plc (LSE/NYSE: GSK) announced it is investing £50 million into a major new five-year collaboration with the University of Cambridge and Cambridge University Hospitals, to accelerate research and development into immune-related diseases. The collaboration, which will be called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC), builds on GSK and Cambridge University’s existing scientific relationship and will aim to find ways to more pre…